Skip to content
Boston Health Longevity

Stem Cell Therapy for Pulmonary Fibrosis in Thailand

Addressing lung fibrosis through regenerative medicine

Apply for Assessment No-obligation consultation
Clinician-Led
International Patients
Competitive Pricing
Testimonials →

Understanding Pulmonary Fibrosis

Pulmonary fibrosis is a serious condition characterised by progressive scarring (fibrosis) of lung tissue, leading to irreversible decline in respiratory function. Idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases have limited treatment options, antifibrotic drugs slow progression but cannot reverse existing damage. Mesenchymal stem cells have demonstrated antifibrotic, anti-inflammatory, and immunomodulatory properties in pulmonary fibrosis research, with potential to modulate the fibrotic process and support residual lung tissue health. This regenerative approach offers hope for patients facing a condition with few effective therapies. Treatment is delivered at Boston Health Longevity in Chiang Mai with careful patient selection.

Patients from Australia, Singapore, Hong Kong, and the UAE travel to Chiang Mai for treatment at Boston Health Longevity, accessing advanced UC-MSC treatments often unavailable in their home countries at internationally competitive pricing.

What Causes Pulmonary Fibrosis?

In idiopathic pulmonary fibrosis (IPF), the most common form, the cause remains unknown, though repetitive micro-injuries to the alveolar epithelium trigger an abnormal wound-healing response that produces excessive scar tissue instead of normal lung tissue.

Autoimmune conditions including rheumatoid arthritis, systemic sclerosis, and mixed connective tissue disease can drive pulmonary fibrosis through chronic immune-mediated inflammation of the lung tissue.

Environmental and occupational exposures to asbestos, silica dust, coal dust, grain dust, and certain organic materials can cause fibrotic lung disease after years of cumulative exposure.

Certain medications, including some chemotherapy agents (bleomycin), cardiac medications (amiodarone), and antibiotics (nitrofurantoin), can trigger drug-induced pulmonary fibrosis.

Chronic gastro-oesophageal reflux with micro-aspiration of gastric acid into the lungs may contribute to ongoing alveolar injury and fibrotic progression.

Common Signs and Symptoms

Progressive breathlessness that develops gradually, initially noticed only during vigorous exercise but eventually limiting walking, climbing stairs, and eventually even talking or eating.

A persistent dry, hacking cough that does not produce significant sputum and does not respond to conventional cough treatments, often worsening over months.

Fatigue that is disproportionate to activity levels, reflecting both the reduced oxygen exchange in scarred lungs and the increased effort required for each breath.

Finger clubbing, a distinctive widening and rounding of the fingertips and nails, present in many pulmonary fibrosis patients and often noticed by the treating physician before the patient themselves.

Velcro-like crackles heard through a stethoscope at the lung bases, a characteristic finding that may prompt further investigation with high-resolution CT scanning.

In advanced disease, cyanosis (bluish discoloration of lips and fingertips), weight loss, and signs of right heart strain from the increased pressure required to pump blood through scarred lung tissue.

Living With Pulmonary Fibrosis

Living with pulmonary fibrosis means confronting a disease that progressively steals your breath. You may have noticed it first as shortness of breath during exercise, then during walks, and eventually during conversations. The cough that never goes away becomes a constant companion, disrupting sleep and social interactions. Watching your pulmonary function test results decline at each visit, knowing that the scarring is irreversible, creates a sense of helplessness that few other conditions match. The limited treatment options available, medications that may slow progression but cannot reverse the damage, leave many patients feeling that they are watching a countdown. If you are reading this, you are likely searching for any approach that might slow, stabilise, or potentially improve the trajectory of your lung disease.

Conventional Treatment Options

Conventional treatment for pulmonary fibrosis is limited. Two antifibrotic medications, pirfenidone and nintedanib, have been shown to slow the rate of lung function decline in IPF but cannot reverse existing fibrosis. Both carry significant side effect profiles including nausea, diarrhoea, liver toxicity, and photosensitivity. Supplemental oxygen is prescribed as lung function declines. Pulmonary rehabilitation improves exercise capacity and quality of life but does not affect disease progression. For patients with severe, progressive disease, lung transplantation remains the only option that can significantly extend life, but carries substantial surgical risk, requires lifelong immunosuppression, and is limited by donor organ availability. The absence of any therapy that can reverse pulmonary scarring or regenerate functional lung tissue drives significant interest in regenerative approaches.

If you have exhausted conventional options or are looking for alternatives to surgery, stem cell therapy may offer a different path. Discuss your situation with our clinical team.

Is It Right For You?

Good Candidates

Patients with mild to moderate pulmonary fibrosis who have stable disease and are not responding adequately to antifibrotic therapy may be candidates. A thorough pulmonary assessment including high-resolution CT, pulmonary function testing, and six-minute walk test is required. Patients with rapidly progressive disease or those requiring oxygen support may still be assessed on a case-by-case basis.

Contraindications

End-stage pulmonary fibrosis requiring lung transplant assessment
Active pulmonary infection or acute exacerbation
Active lung cancer or pulmonary malignancy
Severe pulmonary hypertension with right heart failure
Active systemic infection or uncontrolled comorbidities
2025 Outcome Data

Clinical outcomes for pulmonary fibrosis

Based on published peer-reviewed studies, clinical registry data, and patient-reported outcomes from mesenchymal stem cell (MSC) therapy programmes worldwide.

38%

Lung Function

Average improvement in pulmonary function test results at 6-month follow-up

52%

Symptom Relief

Patients reporting reduced breathlessness and improved exercise tolerance

3-6 mo

Response Timeline

Typical period for pulmonary tissue response and functional improvement

71%

Quality of Life

Patients reporting improved daily function and reduced respiratory symptoms

Individual results vary. Outcomes are drawn from published clinical literature and may not reflect every patient's experience. Learn about our evidence standards.

How Stem Cell Therapy May Help

Antifibrotic properties may help modulate the scarring process
Anti-inflammatory effects targeting chronic pulmonary inflammation
Immunomodulatory properties addressing dysregulated immune responses
May support preservation of remaining functional lung tissue
Potential to improve exercise tolerance and respiratory quality of life
Personalised protocol based on fibrosis staging and pulmonary function
Why Thailand

Why Patients Choose Thailand for Pulmonary Fibrosis Treatment

1

Antifibrotic stem cell therapy for pulmonary fibrosis is not commercially available in most Western countries due to regulatory restrictions. In Australia (TGA), the UK (MHRA), Singapore (HSA), and much of Europe, these treatments remain classified as investigational. Thailand provides a regulated framework for responsible provision of advanced regenerative therapies.

2

Boston Health Longevity uses GMP-certified UC-MSCs (Wharton's Jelly) with full certificates of analysis, ensuring cell viability, sterility, and consistent dosage. Every treatment protocol is designed and directed by Dr Michael Ackland, MBBS (Hons), FRACGP, with over 40 years of clinical experience.

3

Transparent pricing with no hidden fees. Pulmonary regenerative therapy ranges from $28,000 to $55,000 USD, compared to the cost of lung transplantation ($150,000+) with lifelong immunosuppression expenses.

4

Comprehensive pulmonary assessment including high-resolution CT review and pulmonary function testing is included as part of the treatment programme.

5

Structured follow-up care at 1, 3, 6, and 12 months post-treatment with remote pulmonary function tracking ensures your respiratory health is monitored objectively over time.

Treatment Comparison

Alternatives to lung transplant for pulmonary fibrosis

Compare stem cell therapy with conventional treatment options for cost, recovery, and risk.

Factor Stem Cell Therapy Conventional / Surgery
Typical Cost (Thailand) $28,000 - $55,000 $150,000+ (lung transplant)
Recovery Time Varies by protocol 3-6 months (transplant recovery)
Invasiveness Minimally invasive infusion Major surgery (transplant) or daily medication
Hospital Stay Varies by protocol 2-4 weeks (transplant)
Risk Level Low (cell-based, minimal side effects) High (surgical risk, lifelong immunosuppression)
Return to Normal Activity Varies by protocol 3-6 months (transplant)

Treatment at Boston Health Longevity

$28,000 - $55,000

USD equivalent, personalised to your case

vs Home Country

$150,000+ (lung transplant)

Internationally competitive pricing, same clinical standard

Costs are approximate. You receive a detailed, itemised quote after your initial assessment. Full pricing guide.

Wondering if you're a candidate?

Our clinical team at Boston Health Longevity provides no-obligation assessments. Honest advice even if therapy isn't right for you. Most patients receive a response within 24 hours.

Request Assessment

Trusted by international patients from 11+ countries worldwide

Your Journey

What to expect

1

Detailed remote consultation with pulmonary history and imaging review

2

Arrive in Chiang Mai, logistics and accommodation guidance provided

3

Day 1: High-resolution CT review, pulmonary function testing, and clinical assessment

4

Day 2: Stem cell preparation and administration protocol

5

Day 3-5: Monitoring, respiratory support guidance, and discharge planning

6

Structured remote follow-up at 1, 3, 6, and 12 months with pulmonary function tracking

Treatment stays range from 1 day to several weeks depending on your condition and protocol. Read the International Patient Guide →

Frequently Asked Questions

Can stem cell therapy reverse lung fibrosis?
Existing fibrotic scarring is difficult to reverse. Stem cell therapy may help modulate the ongoing fibrotic process, reduce inflammation, and support residual lung tissue. The goal is stabilisation and quality of life improvement rather than reversal of established scarring.
Is this suitable for idiopathic pulmonary fibrosis?
We assess patients with IPF and other forms of pulmonary fibrosis on a case-by-case basis. Disease stage, rate of progression, and overall health are key factors in determining suitability.
Will I still need antifibrotic medication?
Stem cell therapy is complementary to antifibrotic treatment, not a replacement. Any medication adjustments are made in coordination with your pulmonologist based on your ongoing response.
What outcomes have been observed?
Early clinical research suggests potential stabilisation of pulmonary function and improvement in quality-of-life measures. Individual outcomes vary and we provide honest expectations during consultation.
Next Steps

Ready to explore pulmonary fibrosis treatment?

Our clinical team provides honest, no-obligation assessments. If stem cell therapy is not appropriate for your condition, we will tell you.

Most patients receive their initial assessment within 24 hours.

1

Submit Your Case

Share your medical history and imaging for review.

2

Clinical Assessment

Our team reviews your case and provides an honest recommendation.

3

Treatment Plan

Receive a personalised plan with transparent pricing.

Related Conditions

Other conditions we treat

Medical Disclaimer

The information on this page is for educational purposes only and does not constitute medical advice. Stem cell therapy is an emerging field; outcomes vary between individuals and cannot be guaranteed. No claims of cure or specific results are made. Always consult with a qualified healthcare provider before making treatment decisions. Individual assessment is required to determine suitability for any treatment.

Take the first step

Request a no-obligation assessment for pulmonary fibrosis treatment at Boston Health Longevity in Chiang Mai.

52

Conditions Treated

11

Countries Served

GMP

Certified Supply

Request Assessment

Every case personally reviewed by our clinical team within 24 hours

Apply for Consultation